دورية أكاديمية
أعرض في EDS

Critical roles of long noncoding RNA H19 in cancer.

التفاصيل البيبلوغرافية
العنوان: Critical roles of long noncoding RNA H19 in cancer.
المؤلفون: Darmadi D; Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, Indonesia., Chugaeva UY; Department of Pediatric, Preventive Dentistry and Orthodontics, Institute of Dentistry, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia., Saleh RO; Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq., Hjazi A; Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia., Saleem HM; Department of Biology, College of Science, University of Anbar, Ramadi, Iraq., Ghildiyal P; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India., Alwaily ER; Microbiology Research Group, College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq., Alawadi A; College of Technical Engineering, The Islamic University, Najaf, Iraq.; College of Technical Engineering, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.; College of Technical Engineering, The Islamic University of Babylon, Hillah, Iraq., Alnajar MJ; Anesthesia Techniques, Al-Nisour University College, Baghdad, Iraq., Ihsan A; College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, Iraq.
المصدر: Cell biochemistry and function [Cell Biochem Funct] 2024 Apr; Vol. 42 (3), pp. e4018.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8305874 Publication Model: Print Cited Medium: Internet ISSN: 1099-0844 (Electronic) Linking ISSN: 02636484 NLM ISO Abbreviation: Cell Biochem Funct Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford, England : Wiley-Blackwell
Original Publication: Guildford, Surrey : Butterworth Scientific Ltd., c1983-
مواضيع طبية MeSH: RNA, Long Noncoding*/genetics , RNA, Long Noncoding*/metabolism , Neoplasms*/genetics , Neoplasms*/pathology , Neoplasms*/metabolism, Humans ; Epithelial-Mesenchymal Transition/genetics ; Cell Proliferation ; Apoptosis ; Gene Expression Regulation, Neoplastic ; Cell Movement
مستخلص: Long noncoding RNAs (lncRNAs) are a category of noncoding RNAs characterized by their length, often exceeding 200 nucleotides. There is a growing body of data that indicate the significant involvement of lncRNAs in a wide range of disorders, including cancer. lncRNA H19 was among the initial lncRNAs to be identified and is transcribed from the H19 gene. The H19 lncRNA exhibits significant upregulation in a diverse range of human malignancies, such as breast, colorectal, pancreatic, glioma, and gastric cancer. Moreover, the overexpression of H19 is frequently associated with a worse prognosis among individuals diagnosed with cancer. H19 has been shown to have a role in facilitating several cellular processes, including cell proliferation, invasion, migration, epithelial-mesenchymal transition, metastasis, and apoptosis. This article summarizes the aberrant upregulation of H19 in human malignancies, indicating promising avenues for future investigations on cancer diagnostics and therapeutic interventions.
(© 2024 John Wiley & Sons Ltd.)
References: Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343‐351.
Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294‐297.
Mattick JS, Makunin IV. Non‐coding RNA. Hum Mol Gen. 2006;15(suppl 1):R17‐R29.
Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. Mol Cell Biol. 1990;10:28‐36.
Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. In: Rao M. R. S., ed. Long Non Coding RNA Biology. Springer; 2017:1‐46.
Yang J, Qi M, Fei X, Wang X, Wang K. LncRNA H19: a novel oncogene in multiple cancers. Int J Biol Sci. 2021;17(12):3188‐3208.
Zhang R, Xia LQ, Lu WW, Zhang J, Zhu JS. LncRNAs and cancer. Oncol Lett. 2016;12(2):1233‐1239.
Khorkova O, Hsiao J, Wahlestedt C. Basic biology and therapeutic implications of lncRNA. Adv Drug Deliv Rev. 2015;87:15‐24.
Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016;126(8):2775‐2782.
Hessels D, Klein Gunnewiek JMT, van Oort I, et al. DD3PCA3‐based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8‐16.
Zheng R, Du M, Wang X, et al. Exosome–transmitted long non‐coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer. 2018;17:143.
Liu D, Li Y, Luo G, et al. LncRNA SPRY4‐IT1 sponges miR‐101‐3p to promote proliferation and metastasis of bladder cancer cells through up‐regulating EZH2. Cancer Lett. 2017;388:281‐291.
Zhang K, Luo Z, Zhang Y, et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer. Cancer Biomark. 2016;17(2):187‐194.
Chou J, Wang B, Zheng T, et al. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR‐1 with cdc42. Biochem Biophys Res Commun. 2016;472(1):262‐269.
Xu C, Yang M, Tian J, Wang X, Li Z. MALAT‐1: a long non‐coding RNA and its important 3'end functional motif in colorectal cancer metastasis. Int J Oncol. 2011;39(1):169‐175.
Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro‐oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616‐1625.
Zhang J, Qiu WQ, Zhu H, et al. HOTAIR contributes to the carcinogenesis of gastric cancer via modulating cellular and exosomal miRNAs level. Cell Death Dis. 2020;11(9):780.
Li L, Geng Y, Feng R, et al. The human RNA surveillance factor UPF1 modulates gastric cancer progression by targeting long non‐coding RNA MALAT1. Cell Physiol Biochem. 2017;42(6):2194‐2206.
Li C, Miao R, Liu S, et al. Down‐regulation of miR‐146b‐5p by long non‐coding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget. 2017;8(17):28683‐28695.
Shi W, Wu Q, Li S, et al. Upregulation of the long non‐coding RNA PCAT‐1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma. Tumor Biol. 2015;36:2501‐2507.
Di W, Li Q, Shen W, Guo H, Zhao S. The long non‐coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the miR‐1‐CCND2 axis. Am J Cancer Res. 2017;7(6):1298‐1309.
Yang F, Peng Z, Ji W, et al. LncRNA CCAT1 up‐regulates ATG5 to enhance autophagy and promote gastric cancer development by absorbing miR‐140‐3p. Dig Dis Sci. 2022;67(8):3725‐3741.
Huang Y, Xia L, Tan X, et al. Molecular mechanism of lncRNA SNHG12 in immune escape of non‐small cell lung cancer through the HuR/PD‐L1/USP8 axis. Cell Mol Biol Lett. 2022;27(1):43.
Zhang Y, Dong X, Guo X, et al. LncRNA‐BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancer. Mol Cancer. 2023;22(1):41.
Shi C‐J, Xue Z‐H, Zeng W‐Q, et al. LncRNA‐NEF suppressed oxaliplatin resistance and epithelial‐mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. Cancer Gene Ther. 2023;30:855‐865.
Li H, Yu B, Li J, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5(8):2318‐2329.
Ye Y, Shen A, Liu A. Long non‐coding RNA H19 and cancer: a competing endogenous RNA. Bull Cancer. 2019;106(12):1152‐1159.
Yang M, Zhang M, Wang Q, et al. Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta‐analysis. BMC Cancer. 2023;23(1):688.
Wang Y, Zeng J, Chen W, Fan J, Hylemon PB, Zhou H. Long non‐coding RNA H19: a novel oncogene in liver cancer. Non‐Coding RNA. 2023;9(2):19.
Zhao J, Xu J, Wu M, et al. LncRNA H19 regulates breast cancer DNA damage response and sensitivity to PARP inhibitors via binding to ILF2. Int J Mol Sci. 2023;24(11):9157.
Zhao H, Jiang R, Zhang C, Feng Z, Wang X. LncRNA H19‐rich extracellular vesicles derived from gastric cancer stem cells facilitate tumorigenicity and metastasis via mediating intratumor communication network. J Transl Med. 2023;21(1):238.
Zhang R, Zeng Y, Deng JL. Long non‐coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors. Clin Exp Med. 2023;23(5):1425‐1440.
Hooker QS. Elucidating the Role of Long Non‐Coding RNA H19 in Glioblastoma Multiforme. Hofstra University; 2023.
Zhang X, Luo M, Zhang J, et al. The role of lncRNA H19 in tumorigenesis and drug resistance of human cancers. Front Genet. 2022;13:1005522.
Sahin Y. LncRNA H19 is a potential biomarker and correlated with immune infiltration in thyroid carcinoma. Clin Exp Med. 2023;23:841‐851.
Qian B, Wang DM, Gu XS, et al. LncRNA H19 serves as a ceRNA and participates in non‐small cell lung cancer development by regulating microRNA‐107. Eur Rev Med Pharmacol Sci. 2018;22(18):5946‐5953.
Ghafouri‐Fard S, Shoorei H, Bahroudi Z, Abak A, Taheri M. The role of H19 lncRNA in conferring chemoresistance in cancer cells. Biomed Pharmacother. 2021;138:111447.
Alipoor B, Parvar SN, Sabati Z, Ghaedi H, Ghasemi H. An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance. Mol Biol Rep. 2020;47:6357‐6374.
Wang J, Wang X, Chen T, Jiang L, Yang Q. Huaier extract inhibits breast cancer progression through a LncRNA‐H19/MiR‐675‐5p pathway. Cell Physiol Biochem. 2017;44(2):581‐593.
Si X, Zang R, Zhang E, et al. LncRNA H19 confers chemoresistance in ERα‐positive breast cancer through epigenetic silencing of the pro‐apoptotic gene BIK. Oncotarget. 2016;7(49):81452‐81462.
Zhu Q‐N, Wang G, Guo Y, et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A‐MDR1 pathway. Oncotarget. 2017;8(54):91990‐92003.
Xu J, Wang Z, Lu W, et al. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract2019;215(6):152374.
Li Y, Ma H‐Y, Hu X‐W, et al. LncRNA H19 promotes triple‐negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020;20:200.
Shima H, Kida K, Adachi S, et al. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res Treat. 2018;170:507‐516.
Han J, Han B, Wu X, et al. Knockdown of lncRNA H19 restores chemo‐sensitivity in paclitaxel‐resistant triple‐negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol. 2018;359:55‐61.
Gao H, Hao G, Sun Y, Li L, Wang Y. Long non‐coding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. Onco Targets Ther. 2018;11:8001‐8012.
Si H, Chen P, Li H, Wang X. Long non‐coding RNA H19 regulates cell growth and metastasis via miR‐138 in breast cancer. Am J Transl Res. 2019;11(5):3213‐3225.
Li Z, Li Y, Li Y, et al. Long non‐coding RNA H19 promotes the proliferation and invasion of breast cancer through up‐regulating DNMT1 expression by sponging miR‐152. J Biochem Mol Toxicol. 2017;31(9):e21933.
Sun Z, Zhang C, Wang T, Shi P, Tian X, Guo Y. Correlation between long non‐coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer. J Cancer Res Ther. 2019;15(4):933‐940.
Wang Y, Zhou P, Li P, Yang F, Gao X. Long non‐coding RNA H19 regulates proliferation and doxorubicin resistance in MCF‐7 cells by targeting PARP1. Bioengineered. 2020;11(1):536‐546.
Wang Y, Wu Z, Li Y, et al. Long non‐coding RNA H19 promotes proliferation, migration and invasion and inhibits apoptosis of breast cancer cells by targeting miR‐491‐5p/ZNF703 axis. Cancer Manag Res. 2020;12:9247‐9258.
Zhong G, Lin Y, Wang X, Wang K, Liu J, Wei W. H19 knockdown suppresses proliferation and induces apoptosis by regulating miR‐130a‐3p/SATB1 in breast cancer cells. Onco Targets Ther. 2020;13:12501‐12513.
Yang W, Ning N, Jin X. The lncRNA H19 promotes cell proliferation by competitively binding to miR‐200a and derepressing β‐catenin expression in colorectal cancer. BioMed Res Int. 2017;2017:2767484.
Ren J, Ding L, Zhang D, et al. Carcinoma‐associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932‐3948.
Ding D, Li C, Zhao T, Li D, Yang L, Zhang B. LncRNA H19/miR‐29b‐3p/PGRN axis promoted epithelial‐mesenchymal transition of colorectal cancer cells by acting on Wnt signaling. Mol Cells. 2018;41(5):423‐435.
Han D, Gao X, Wang M, et al. Long non‐coding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3. Oncotarget. 2016;7(16):22159‐22173.
Zhang Y, Huang W, Yuan Y, et al. Long non‐coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39(1):1‐15.
Wang M, Han D, Yuan Z, et al. Long non‐coding RNA H19 confers 5‐Fu resistance in colorectal cancer by promoting SIRT1‐mediated autophagy. Cell Death Dis. 2018;9(12):1149.
Yang W, Redpath RE, Zhang C, Ning N. Long non‑coding RNA H19 promotes the migration and invasion of colon cancer cells via MAPK signaling pathway. Oncol Lett. 2018;16(3):3365‐3372.
Chen S, Bu D, Ma Y, et al. H19 overexpression induces resistance to 1, 25 (OH) 2D3 by targeting VDR through miR‐675‐5p in colon cancer cells. Neoplasia. 2017;19(3):226‐236.
Zichittella C, Loria M, Celesia A, et al. Long non‐coding RNA H19 enhances the pro‐apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells. Front Pharmacol. 2023;14:1275833.
Zhao Y, Feng C, Li Y, Ma Y, Cai R. LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR‐200a function. Mol Cell Biochem. 2019;460:1‐8.
Lei Y, Guo W, Chen B, Chen L, Gong J, Li W. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer. Oncol Rep. 2018;40(6):3438‐3446.
Pan R, Zhou H. Exosomal transfer of lncRNA H19 promotes erlotinib resistance in non‐small cell lung cancer via miR‐615‐3p/ATG7 axis. Cancer Manag Res. 2020;12:4283‐4297.
Zhang E, Li W, Yin D, et al. c‐Myc‐regulated long non‐coding RNA H19 indicates a poor prognosis and affects cell proliferation in non‐small‐cell lung cancer. Tumor Biol. 2016;37:4007‐4015.
Cui J, Mo J, Luo M, et al. c‐Myc‐activated long non‐coding RNA H19 downregulates miR‐107 and promotes cell cycle progression of non‐small cell lung cancer. Int J Clin Exp Pathol. 2015;8(10):12400‐12409.
Zhou Y, Sheng B, Xia Q, Guan X, Zhang Y. Association of long non‐coding RNA H19 and microRNA‐21 expression with the biological features and prognosis of non‐small cell lung cancer. Cancer Gene Ther. 2017;24(8):317‐324.
Xu J‐L, Hua T, Ding J, Fan Y, Liu Z‐J, Lian J‐W. FOXF2 aggravates the progression of non‐small cell lung cancer through targeting lncRNA H19 to downregulate PTEN. Eur Rev Med Pharmacol Sci. 2019;23(24):10796‐10802.
Liao S, Yu C, Liu H, Zhang C, Li Y, Zhong X. Long non‐coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E‐cadherin, N‐cadherin, and vimentin. Onco Targets Ther. 2019;12:4099.
Huang Z, Lei W, Hu HB, Zhang H, Zhu Y. H19 promotes non‐small‐cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR‐17. J Cell Physiol. 2018;233(10):6768‐6776.
Liu L, Liu L, Lu S. lncRNA H19 promotes viability and epithelial‐mesenchymal transition of lung adenocarcinoma cells by targeting miR‐29b‐3p and modifying STAT3. Int J Oncol. 2019;54(3):929‐941.
Huang T, Wen Y, Peng B, Ding G, Yang L, Wang Z. Up‐regulated lncRNA H19 promotes non‐small cell lung cancer cell proliferation through miR‐138/PDK1 axis. Int J Clin Exp Pathol. 2017;10(8):9012‐9020.
Li X, Lv F, Li F, et al. Long non‐coding RNA H19 facilitates small cell lung cancer tumorigenesis through miR‐140‐5p/FGF9 axis. Onco Targets Ther. 2020;13:3525‐3534.
Bivona TG, Doebele RC. A framework for understanding and targeting residual disease in oncogene‐driven solid cancers. Nature Med. 2016;22(5):472‐478.
Huang Z, Ma Y, Zhang P, Si J, Xiong Y, Yang Y. Long non‐coding RNA H19 confers resistance to gefitinib via miR‐148b‐3p/DDAH1 axis in lung adenocarcinoma. Anti‐Cancer Drugs. 2020;31(1):44‐54.
Yang F, Bi J, Xue X, et al. Up‐regulated long non‐coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012;279(17):3159‐3165.
Li H, Yu B, Li J, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5:2318‐2329.
Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long non‐coding RNA H19‐derived miR‐675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem Biophys Res Commun. 2014;448(3):315‐322.
Liu J, Wang G, Zhao J, et al. LncRNA H19 promoted the epithelial to mesenchymal transition and metastasis in gastric cancer via activating Wnt/β‐catenin signaling. Dig Dis. 2022;40(4):436‐447.
Yan J, Zhang Y, She Q, et al. Long non‐coding RNA H19/miR‐675 axis promotes gastric cancer via FADD/Caspase 8/Caspase 3 signaling pathway. Cell Physiol Biochem. 2017;42(6):2364‐2376.
Gan L, Lv L, Liao S. Long non‑coding RNA H19 regulates cell growth and metastasis via the miR‑22‑3p/Snail1 axis in gastric cancer. Int J Oncol. 2019;54(6):2157‐2168.
Chen M‐J, Deng J, Chen C, Hu W, Yuan Y‐C, Xia Z‐K. LncRNA H19 promotes epithelial mesenchymal transition and metastasis of esophageal cancer via STAT3/EZH2 axis. Int J Biochem Cell Biol. 2019;113:27‐36.
Li Z, Niu Y. Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in Chinese population. Minerva Urol Nefrol. 2019;71(2):161‐167.
Wang J, Yang K, Yuan W, Gao Z. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307‐9316.
Lv M, Zhong Z, Huang M, Tian Q, Jiang R, Chen J. lncRNA H19 regulates epithelial–mesenchymal transition and metastasis of bladder cancer by miR‐29b‐3p as competing endogenous RNA. Biochim Biophys Acta (BBA) Mol Cell Res. 2017;1864(10):1887‐1899.
Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non‐coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E‐cadherin expression. Cancer Lett. 2013;333(2):213‐221.
Li S, Yu Z, Chen S‐S, et al. The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long non‐coding RNA. Paper presented at: Urologic Oncology: Seminars and Original Investigations. 2015.
Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Up‐regulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J. 2013;280(7):1709‐1716.
Liu C, Chen Z, Fang J, Xu A, Zhang W, Wang Z. H19‐derived miR‐675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumor Biol. 2016;37:263‐270.
Guo Y, Sun W, Gao W, et al. Long non‐coding RNA H19 derived from M2 tumor‐associated macrophages promotes bladder cell autophagy via stabilizing ULK1. J Oncol. 2022;2022:3465549.
Wang F, Rong L, Zhang Z, et al. LncRNA H19‐derived miR‐675‐3p promotes epithelial‐mesenchymal transition and stemness in human pancreatic cancer cells by targeting the STAT3 pathway. J Cancer. 2020;11(16):4771‐4782.
Sun Y, Zhu Q, Yang W, et al. LncRNA H19/miR‐194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. J Cell Biochem. 2019;120(3):3874‐3886.
Luo Y, Yan B, Liu L, et al. Sulforaphane inhibits the expression of long non‐coding RNA H19 and its target APOBEC3G and thereby pancreatic cancer progression. Cancers. 2021;13(4):827.
Yoshimura H, Matsuda Y, Yamamoto M, et al. Reduced expression of the H19 long non‐coding RNA inhibits pancreatic cancer metastasis. Lab Invest. 2018;98(6):814‐824.
Li J, Hou S, Ye Z, Wang W, Hu X, Hang Q. Long non‐coding RNAs in pancreatic cancer: biologic functions, mechanisms, and clinical significance. Cancers. 2022;14(9):2115.
Wang J, Zhao L, Shang K, et al. Long non‐coding RNA H19, a novel therapeutic target for pancreatic cancer. Mol Med. 2020;26(1):30.
Sasaki N, Toyoda M, Yoshimura H, et al. H19 long non‐coding RNA contributes to sphere formation and invasion through regulation of CD24 and integrin expression in pancreatic cancer cells. Oncotarget. 2018;9(78):34719‐34734.
Chen L, Wang Y, He J, Zhang C, Chen J, Shi D. Long non‐coding RNA H19 promotes proliferation and invasion in human glioma cells by downregulating miR‐152. Oncol Res. 2018;26(9):1419‐1428.
Shi Y, Wang Y, Luan W, et al. Long non‐coding RNA H19 promotes glioma cell invasion by deriving miR‐675. PLoS One. 2014;9(1):e86295.
Zhao H, Peng R, Liu Q, et al. The lncRNA H19 interacts with miR‐140 to modulate glioma growth by targeting iASPP. Arch Biochem Biophys. 2016;610:1‐7.
Zhou Q, Liu Z‐Z, Wu H, Kuang W‐L. LncRNA H19 promotes cell proliferation, migration, and angiogenesis of glioma by regulating Wnt5a/β‐catenin pathway via targeting miR‐342. Cell Mol Neurobiol. 2022;42(4):1065‐1077.
Fazi B, Garbo S, Toschi N, et al. The lncRNA H19 positively affects the tumorigenic properties of glioblastoma cells and contributes to NKD1 repression through the recruitment of EZH2 on its promoter. Oncotarget. 2018;9(21):15512‐15525.
Chen X, Li Y, Zuo C, et al. Long non‐coding RNA H19 regulates glioma cell growth and metastasis via miR‐200a‐mediated CDK6 and ZEB1 expression. Front Oncol. 2021;11:757650.
Zhao W, Lin X, Han H, et al. Long non‐coding RNA H19 contributes to the proliferation and autophagy of glioma cells through mTOR/ULK1 pathway. Neuroreport. 2021;32(5):352‐358.
Jiang P, Wang P, Sun X, et al. Knockdown of long non‐coding RNA H19 sensitizes human glioma cells to temozolomide therapy. Onco Targets Ther. 2016;9:3501‐3509.
Kuang Y, Bing Z, Jin X, Li Q. LncRNA H19 upregulation participates in the response of glioma cells to radiation. BioMed Res Int. 2021;2021:1‐10.
Ren J, Fu J, Ma T, et al. LncRNA H19‐elevated LIN28B promotes lung cancer progression through sequestering miR‐196b. Cell Cycle. 2018;17(11):1372‐1380.
Zhou X, Ye F, Yin C, Zhuang Y, Yue G, Zhang G. The interaction between MiR‐141 and lncRNA‐H19 in regulating cell proliferation and migration in gastric cancer. Cell Physiol Biochem. 2015;36(4):1440‐1452.
Li X, Yang H, Wang J, et al. High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. Pathol Res Pract. 2019;215(11):152638.
Ma C, Nong K, Zhu H, et al. H19 promotes pancreatic cancer metastasis by derepressing let‐7's suppression on its target HMGA2‐mediated EMT. Tumor Biol. 2014;35:9163‐9169.
Jia P, Cai H, Liu X, et al. Long non‐coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma‐associated endothelial cells by inhibiting microRNA‐29a. Cancer Lett. 2016;381(2):359‐369.
Hu Q, Yin J, Zeng A, et al. H19 functions as a competing endogenous RNA to regulate EMT by sponging miR‐130a‐3p in glioma. Cell Physiol Biochem. 2018;50(1):233‐245.
معلومات مُعتمدة: PSAU/2024/R/1445 Deanship of Scientific Research, Prince Sattam bin Abdulaziz University
فهرسة مساهمة: Keywords: H9; biomarker; cancer; diagnosis; lncRNA; prognosis; tretament
المشرفين على المادة: 0 (RNA, Long Noncoding)
0 (H19 long non-coding RNA)
تواريخ الأحداث: Date Created: 20240422 Date Completed: 20240423 Latest Revision: 20240423
رمز التحديث: 20240424
DOI: 10.1002/cbf.4018
PMID: 38644608
قاعدة البيانات: MEDLINE
الوصف
تدمد:1099-0844
DOI:10.1002/cbf.4018